Global Tafasitamab Market Strategic Research Report

Scope of the Report

The global Tafasitamab market size is predicted to grow from US$ 333 million in 2025 to US$ 802 million in 2032; it is expected to grow at a CAGR of 12.2% from 2026 to 2032.

Tafasitamab is a humanized CD19-targeted monoclonal antibody primarily used in the treatment of B-cell malignancies. It specifically binds to the CD19 antigen expressed on the surface of B cells, inducing antibody-dependent cellular cytotoxicity (ADCC) and other immune-mediated mechanisms, thereby promoting the elimination of malignant B cells. Tafasitamab is typically used in combination with immunomodulatory agents such as lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It has significant clinical value in the field of hematologic cancer targeted therapy.In 2025, global production of tafasitamab reached approximately 150,000units.

Tafasitamab, as a CD19-targeted monoclonal antibody, occupies an important niche in the treatment market for B-cell non-Hodgkin lymphoma, particularly in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). With the steady increase in the global incidence of hematologic malignancies and the growing demand for novel immuno-targeted therapies, the CD19-targeted drug market is gradually expanding. Tafasitamab has demonstrated clinical efficacy in combination with lenalidomide, enabling it to gain guideline recommendations and improve its clinical penetration. From a competitive landscape perspective, this field is not only dominated by long-established CD20 monoclonal antibodies such as rituximab, but also faces competitive pressure from emerging CD19/CD79b-targeted therapies. Looking ahead, with the accumulation of real-world evidence, expansion of indications, and commercialization in emerging markets, the market size of tafasitamab is expected to maintain steady growth, continuing to play an important role in the precision treatment landscape of B-cell lymphoma.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Tafasitamab market?

What factors are driving Tafasitamab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Tafasitamab market opportunities vary by end market size?

How does Tafasitamab break out by Type, by Application?

This report presents a comprehensive overview of the global Tafasitamab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Combination With Immunomodulatory Agents (Such As Lenalidomide)
• Combination With Chemotherapy Or Other Targeted Therapies

Segment by Specification

• 200 mg / vial
• 800 mg/vial

Segment by Production Technology

• Innovator
• Generic

Segment by Dosage Form

• Lyophilized Powder for Injection
• Injection Solution

Segment by Application

• Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
• B-Cell Non-Hodgkin Lymphoma (B-NHL)
• CD19-Positive Hematologic Malignancies
• Precision Hematologic Cancer Therapy
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Tafasitamab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL), B-Cell Non-Hodgkin Lymphoma (B-NHL), CD19-Positive Hematologic Malignancies evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact